Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
2.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
3.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
4.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. doi: 10.1016/j.juro.2009.01.047. Epub 2009 Mar 14. Review.

5.

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.

Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Review.

6.

Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Clinton TN, Woldu SL, Raj GV.

Expert Opin Pharmacother. 2017 Jun;18(8):825-832. doi: 10.1080/14656566.2017.1328056. Epub 2017 May 19. Review.

PMID:
28480768
7.

[Cardiovascular risks of androgen deprivation therapy for prostate cancer].

Miller K.

Urologe A. 2016 May;55(5):627-31. doi: 10.1007/s00120-015-0021-1. Review. German.

PMID:
27003571
8.

Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.

Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, Zhao D, Niu Y.

BMC Cancer. 2016 Mar 3;16:180. doi: 10.1186/s12885-016-2221-5. Review.

9.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS.

Cancer. 2005 Apr 15;103(8):1615-24. Review.

11.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2013 Jan;189(1 Suppl):S34-42; discussion S43-4. doi: 10.1016/j.juro.2012.11.017. Review.

PMID:
23234628
12.

Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.

Greiman AK, Keane TE.

Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5. Review.

PMID:
28417429
13.

Prostate cancer, osteoporosis and fracture risk.

Allain TJ.

Gerontology. 2006;52(2):107-10. Review.

PMID:
16508318
14.

Androgen deprivation therapy for prostate cancer: new concepts and concerns.

Smith MR.

Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. Review.

15.

A review of the use of histrelin acetate in the treatment of prostate cancer.

Crawford ED.

BJU Int. 2009 Mar;103 Suppl 2:14-22. doi: 10.1111/j.1464-410X.2009.08384.x. Review. No abstract available.

16.

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer.

Smith MR.

J Urol. 2004 Nov;172(5 Pt 2):S52-6; discussion S56-7. Review.

PMID:
15535444
17.

[Keyrole of endocrinology in the victory against prostate cancer].

Labrie F.

Bull Cancer. 2006 Sep;93(9):949-58. Review. French.

18.

Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy.

Monzó-Gardiner JI, Herranz-Amo F.

Actas Urol Esp. 2015 Oct;39(8):518-22. doi: 10.1016/j.acuro.2015.01.004. Epub 2015 Feb 25. Review. English, Spanish.

PMID:
25726508
19.

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ.

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Review.

PMID:
19025432
20.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

Supplemental Content

Support Center